Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

BACKGROUND: Biliary tract cancer (BTC) has a poor prognosis and lacks a standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast growth factor receptor (FGFR) 4, and platelet-derived growth factor receptor (PDGFR) are highly expressed in BTC. Therefore, lenvatinib (a k...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Makoto, Ikeda, Masafumi, Sasaki, Takashi, Nagashima, Fumio, Mizuno, Nobumasa, Shimizu, Satoshi, Ikezawa, Hiroki, Hayata, Nozomi, Nakajima, Ryo, Morizane, Chigusa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667859/
https://www.ncbi.nlm.nih.gov/pubmed/33198671
http://dx.doi.org/10.1186/s12885-020-07365-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667859/
https://www.ncbi.nlm.nih.gov/pubmed/33198671
http://dx.doi.org/10.1186/s12885-020-07365-4

Ejemplares similares